0 of 5 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
Currently, how confident are you in your ability to:
1 = not confident, 2 = somewhat confident, 3 = confident, 4 = very confident, 5 = extremely confident, N/A = not applicable to me
Develop personalized treatment plans for patients with dyslipidemia while incorporating PCSK9 inhibitor therapeutics?
Apply PCSK9 inhibitor therapeutics when treating patients with dyslipidemia?
Indicate how often you CURRENTLY use each the following clinical practice strategy for your patients with dyslipidemia.
*1 = Never, 2 = Not often, 3 = Sometimes, 4 = Often, 5 = Always, N/A = Not applicable to me
Implement new and emerging clinical trial data of PCSK9 inhibitors to treat patients with dyslipidemia.
1. The FOURIER Trial was a randomized double-blind study of evolocumab and placebo. Which of the following represents the percentage of mean reduction in LDL cholesterol with evolocumab?
2. The ODYSSEY Outcomes Trial was a randomized study of alirocumab and placebo. Which of the following represents the all-cause mortality percentage reduction with alirocumab?
3. When comparing the FOURIER Trial and ODYSSEY OUTCOMES Trial, which of the following represents the percentage of high-intensity statin use in both FOURIER and ODYSSEY?